Mouse B7-H3 induces antitumor immunity

Gene Therapy

Volumn 10, Issue 20, 2003, Pages 1728-1734

  Sun, X ^a,b   Vale, M ^a   Leung, E ^a   Kanwar, J R ^a   Gupta, R ^a   Krissansen, G W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b SHANDONG UNIVERSITY   (China)

Author keywords

B7 molecule; Cancer immunotherapy; Costimulation

Indexed keywords

B7 ANTIGEN; B7 H3 ANTIGEN; CD86 ANTIGEN; COMPLEMENTARY DNA; LIPOSOME; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD80; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; DNA; FEMALE; GENE THERAPY; INJECTIONS, INTRALESIONAL; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; THYMUS NEOPLASMS;

ANIMALIA;

EID: 0141851079     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302070     Document Type: Article

References (26)

1. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11: 203-210.
2. Liang L, Sha WC. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002; 14: 384-390.
3. Coyle A, Gutierrez-Ramos J. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2: 203-209.
4. Henry J, Miller M, Pontarotti P. Structure and evolution of the extended B7 family. Immunol Today 1999; 20: 285-288.
5. Yoshinaga SK et al. T cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402: 827-831.
6. Hutloff A et al. ICOS is an inducibte T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263-266.
7. Freeman G et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
8. Latchman Y et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
9. Tseng SY et al. B7-DC a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846.
10. Nishimura H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
11. Nishimura H et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322.
12. Chapoval A et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269-274.
13. + T cells by B7 transfected melanoma cells. Science 1993; 259: 368-370.
14. Chen L et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
15. Baskar S et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687-5690.
16. Kanwar J, Berg R, Lehnert K, Krissansen GW. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Therapy 1999; 6: 1835-1844.
17. Sun X et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001; 8: 638-645.
18. Sun X et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Therapy 2001; 8: 719-727.
19. Kanwar JR, Shen WP, Berg R, Krissansen GW. Effect of survivin antagonists on the growth of established tumors and B7.1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541-1552.
20. Kanwar JR et al. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1-mediated immunotherapy overcomes immune-resistance and leads to the eradication of large tumors. Cancer Res 2000; 61: 1948-1956.
21. Sun M et al. Characterization of mouse and human B7-H3 genes. J Immunol 2002; 168: 6294-6297.
22. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
23. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996; 156: 73-78.
24. Won J et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 1999; 59: 1273-1277.
25. Tannenbaum CS, Hamilton TA. Immune-inflammatory mechanisms in IFNgamma-mediated antitumor activity. Sem Cancer Biol 2000; 10: 113-123.
26. Wilson JL et al. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 1999; 163: 4207-4212.